317 related articles for article (PubMed ID: 17893759)
1. High rates of antimicrobial co-resistance among Enterobacteriaceae: comparative analysis between clinical isolates resistant and susceptible to third-generation cephalosporins.
Goyanes MJ; Cercenado E; Insa R; Morente A; Alcalá L; Bouza E
Rev Esp Quimioter; 2007 Jun; 20(2):216-21. PubMed ID: 17893759
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
[TBL] [Abstract][Full Text] [Related]
4. Resistance in gram-negative bacteria: enterobacteriaceae.
Paterson DL
Am J Med; 2006 Jun; 119(6 Suppl 1):S20-8; discussion S62-70. PubMed ID: 16735147
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England.
Potz NA; Hope R; Warner M; Johnson AP; Livermore DM;
J Antimicrob Chemother; 2006 Aug; 58(2):320-6. PubMed ID: 16735428
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Pfaller MA; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
9. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
[TBL] [Abstract][Full Text] [Related]
11. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
[TBL] [Abstract][Full Text] [Related]
12. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases.
Endimiani A; Paterson DL
Semin Respir Crit Care Med; 2007 Dec; 28(6):646-55. PubMed ID: 18095228
[TBL] [Abstract][Full Text] [Related]
13. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.
Muratani T; Matsumoto T
Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S10-3. PubMed ID: 16829056
[TBL] [Abstract][Full Text] [Related]
14. [In vitro study of combinations between third-generation cephalosporins and aminoglycosides on Enterobacteriaceae].
Fosse T; Soussy CJ; Duval J
Pathol Biol (Paris); 1983 Jun; 31(6):483-7. PubMed ID: 6348654
[TBL] [Abstract][Full Text] [Related]
15. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
DiPersio JR; Dowzicky MJ
Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
[TBL] [Abstract][Full Text] [Related]
16. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
Garau J
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
[TBL] [Abstract][Full Text] [Related]
18. [Phenotypic and genotypic characterization of resistance to third-generation cephalosporins in Enterobacter spp].
Bertona E; Radice M; Rodríguez CH; Barberis C; Vay C; Famiglietti A; Gutkind G
Rev Argent Microbiol; 2005; 37(4):203-8. PubMed ID: 16502641
[TBL] [Abstract][Full Text] [Related]
19. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
[TBL] [Abstract][Full Text] [Related]
20. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007.
Hoban DJ; Bouchillon SK; Hawser SP; Badal RE
Diagn Microbiol Infect Dis; 2010 Jan; 66(1):78-86. PubMed ID: 19733993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
